Get the Stockscreener App
4.49
6.40%
0.27
After Hours:
4.49
Evotec Se Adr stock is traded at $4.49, with a volume of 86,469.
It is up +6.40% in the last 24 hours and up +3.46% over the past month.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
See More
Previous Close:
$4.22
Open:
$4.34
24h Volume:
86,469
Relative Volume:
0.40
Market Cap:
$1.60B
Revenue:
$842.96M
Net Income/Loss:
$-185.63M
P/E Ratio:
-8.5377
EPS:
-0.5259
Net Cash Flow:
$-228.52M
1W Performance:
+7.93%
1M Performance:
+3.46%
6M Performance:
-4.67%
1Y Performance:
-42.66%
1-Day Range:
$4.34
$4.52
1-Week Range:
$4.18
$4.52
52-Week Range:
$2.85
$7.98
Evotec Se Adr Stock (EVO) Company Profile
Compare EVO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EVO
Evotec Se Adr
|
4.49 | 1.60B | 842.96M | -185.63M | -228.52M | -0.5259 |
|
ZTS
Zoetis Inc
|
172.80 | 78.39B | 9.15B | 2.43B | 2.31B | 5.32 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.69 | 43.65B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
HLN
Haleon Plc Adr
|
9.57 | 43.41B | 14.26B | 1.55B | 0 | 0.3383 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.83 | 20.07B | 16.77B | -959.00M | 1.37B | -0.85 |
|
NBIX
Neurocrine Biosciences Inc
|
153.29 | 15.53B | 2.24B | 385.90M | 440.10M | 3.73 |
Evotec Se Adr Stock (EVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-07-24 | Downgrade | Jefferies | Buy → Hold |
| Aug-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jul-29-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-11-24 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-18-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jun-23-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-08-23 | Upgrade | Citigroup | Neutral → Buy |
| Apr-04-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Dec-09-22 | Initiated | H.C. Wainwright | Buy |
| Nov-16-22 | Downgrade | Deutsche Bank | Buy → Hold |
| Aug-10-22 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Mar-02-22 | Resumed | Cowen | Outperform |
| Jan-07-22 | Resumed | Citigroup | Neutral |
View All
Evotec Se Adr Stock (EVO) Latest News
Evotec: Some Recovery Has Come, But Much More Is Expected - Seeking Alpha
Evotec shares surge 20% on Halozyme's 2 billion euro takeover bid - MSN
In-Vitro Toxicology Testing Market Projected to Reach USD 30.06 Bn by 2033 - GlobeNewswire Inc.
Markets Brief: Are Bank Stocks Expensive? - Morningstar
Evotec SE withdraws acquisition offer By Investing.com - Investing.com South Africa
Evotec SE withdraws acquisition offer - Investing.com India
Halozyme ends bid to acquire Evotec at €2 billion valuation - Investing.com
Halozyme outlines plan to acquire Evotec for €2 billion - Investing.com
Halozyme outlines plan to acquire Evotec for €2 billion By Investing.com - Investing.com UK
Halozyme to Fund Proposed Evotec Takeover in Cash, CEO Says - Yahoo Finance
Evotec SE responds to media speculation - Investing.com India
Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion - AOL
Halozyme Therapeutics sinks after confirming $2B Evotec buyout offer - Seeking Alpha
Evotec SE responds to media speculation By Investing.com - Investing.com UK
Halozyme proposes $2 billion acquisition of Evotec - Investing.com India
Earnings call: Evotec SE maintains 2024 outlook amid strategic changes - Investing.com India
Evotec SE ADR earnings beat by $0.02, revenue fell short of estimates - Investing.com
Evotec Reports Strategic Growth Amidst Revenue Challenges - TipRanks
Evotec SE Reports 9M 2024 Results: Strategic Progress and Successful Expansion Amid Challenging Market Conditions - Yahoo Finance
Evotec stock outlook clouded by strategy update delays, warns Jefferies - Investing.com
KZIAKazia Therapeutics Limited American Depositary Shares Latest Stock News & Market Updates - StockTitan
Stock Information - Evotec
Annual General Meeting - Evotec
Investor Relations - Evotec
Earnings call: Evotec SE reports revenue increase, plans cost cuts - Investing.com
Earnings call: Evotec SE revises 2024 outlook amid market challenges By Investing.com - Investing.com Canada
Earnings call: Evotec SE revises 2024 outlook amid market challenges - Investing.com
Bristol Myers' German Partner Evotec Plans Layoffs, Cites 'Challenging Revenues, Profitability' - Yahoo Finance
Dozens of US Stocks Are Newly Undervalued After Market Selloff - Morningstar
Evotec Faces Short-Term Headwinds and Rising Costs, but Long-Term Growth Outlook Remains Positive - Morningstar
Evotec shares crash 36% on profit warning - Investing.com
Healthcare Sector - Morningstar
Earnings call: Evotec SE Q1 2024 results show mixed performance amid challenges - Investing.com Canada
T. Rowe Price Raises Stake in Evotec SE - TipRanks
Evotec (EVO) Inks Drug Discovery Collaboration Deal With J&J - Yahoo Finance
Evotec Se Adr Stock (EVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):